Report #2847740

Received Jun 30, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: AZ
Recovered: Recovered
Vaccinated: May 1, 2025
Onset: May 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Labyrinthitis

Symptom narrative

Labyrinthitis; This non-serious case was reported by a physician via sales rep and described the occurrence of labyrinthitis in a 55-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. In MAY-2025, the patient received the 2nd dose of Shingrix. In MAY-2025, 2 days after receiving Shingrix, the patient experienced labyrinthitis (Verbatim: Labyrinthitis). The outcome of the labyrinthitis was resolved. The reporter considered the labyrinthitis to be related to Shingrix. The company considered the labyrinthitis to be related to Shingrix. Additional Information: GSK Receipt Date: 24-JUN-2025 The physician reported that the patient got labyrinthitis 2 days after second dose and the symptoms resolved several weeks later and occurred within last month.